# A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy Volunteers

> **NCT04358523** · PHASE1 · COMPLETED · sponsor: **Ascletis Pharmaceuticals Co., Ltd.** · enrollment: 50 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ASC18
- **DRUG:** ravidasvir and sofosbuvir
- **DRUG:** ASC18

## Key facts

- **NCT ID:** NCT04358523
- **Lead sponsor:** Ascletis Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-20
- **Primary completion:** 2020-12-15
- **Final completion:** 2020-12-15
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2021-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04358523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04358523, "A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04358523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*